Compare AIRG & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRG | CVM |
|---|---|---|
| Founded | 1995 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 43.3M |
| IPO Year | 2016 | 1987 |
| Metric | AIRG | CVM |
|---|---|---|
| Price | $4.70 | $5.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | 54.5K | ★ 79.8K |
| Earning Date | 02-26-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,737,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.00 | $1.98 |
| 52 Week High | $7.40 | $20.41 |
| Indicator | AIRG | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 64.30 | 42.17 |
| Support Level | $4.12 | $4.90 |
| Resistance Level | $4.66 | $6.75 |
| Average True Range (ATR) | 0.27 | 0.65 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 82.22 | 9.46 |
Airgain Inc is engaged in providing antenna technologies. These technologies can be used to enable performance wireless networking across devices and markets which include connected homes, enterprises, automotive, and the Internet of Things. It also provides solutions to complex radio frequency, engineering challenges, and improving wireless service that require higher throughput, broad coverage footprint, and carrier-grade quality. Geographically, it derives maximum revenue from North America and also has a presence in China and the Rest of the World. The company products include Antenna Plus: Fleet, M2M, IoT Antennas, Carrier-Class Antenna, Embedded Antennas, and External Dipole Antennas.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.